BioGaia AB (publ) (BIOGY)
BioGaia AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Stockholm, AB, SE. The stock last traded at $12.36, up 0.00% on the session, giving a market capitalisation of $1.25B. On trailing twelve-month figures it carries a trailing P/E of 32.54, a net margin of 22.0%. Its beta of 0.32 implies it has historically moved less than the broad market.
BioGaia AB (publ) is a global enterprise dedicated to the development, marketing, and sale of probiotic products, all backed by documented health benefits. The company organizes its activities into three primary divisions: Pediatrics, Adult Health, and 'Other'. Within the Pediatric segment, BioGaia provides items such as liquid drops, oral rehydration solutions, and gut health tablets, alongside supplying probiotic cultures for integration into infant formula. The Adult Health segment offers both digestive health tablets and oral hygiene lozenges, as well as providing cultures that are incorporated into dairy products by its licensees. The 'Other' segment focuses on delivering packaging solutions. BioGaia's product portfolio addresses a wide array of health conditions, including infantile colic and digestive problems in children, acute and antibiotic-associated diarrhea, gingivitis, periodontal disease, general wellness, Helicobacter pylori infections (the bacterium causing gastric ulcers), and low bone density. All of the company's products are sold under the BioGaia brand. Founded in 1990, BioGaia AB (publ) is headquartered in Stockholm, Sweden.
BioGaia AB (publ) is most often compared with the following Healthcare names: